Home > Pressrelease > Pharmaceutical Drug Delivery Market size to exceed $3.2 Tn by 2032

Pharmaceutical Drug Delivery Market size to exceed $3.2 Tn by 2032

  • Published Date: May 3, 2023

Pharmaceutical Drug Delivery Market size is anticipated to cross USD 3.2 trillion by 2032, according to a new research report by Global Market Insights Inc.

Technological developments are expected to support the production of a novel, user-friendly, accurate, and patient-friendly pharmaceutical delivery systems. Major pharmaceutical companies are pumping funds into R&D in order to produce cutting-edge and new drug delivery systems, like needle-free injectors, implants, nanotechnology, and peptide encapsulation. For instance, in May 2022, Pulse NeedleFree launched one of the world’s first needle-free injectors for livestock. The goal was to bring evolution to the animal health industry through the vaccination of animals.

Rising need for effective eye treatments to drive market gains

The pharmaceutical drug delivery market share from the ocular drug delivery segment is expected to record more than 7% CAGR by 2032. Liquid formulations, semi-solid formulations, and ocular devices are the three categories of ocular drug delivery systems. Eye drops and liquid sprays are included in the liquid formulations. The eye ointments and gels make up the semi-solid formulations.

Ocular devices are used to treat eye conditions such as amblyopia, diabetic retinopathy, and cataracts. Fast absorption rates, homogeneous medication delivery, and simple administration are some of the benefits of ocular drug delivery. In 2023, ENTOD Pharmaceuticals launched a new ocular aesthetic range that helps improve eye comfort.

Browse key industry insights spread across 850 pages with 1650 market data tables & 17 figures & charts from the report, “Pharmaceutical Drug Delivery Market - By Route Of Administration {Oral [Solid (Tablets, Capsules, Powder, Pills), Liquid (Syrups, Solutions), Semi-Solid (Gels, Emulsions, Elixirs)], Injectable [Conventional [Material (Glass, Plastic Syringes), Product (Fillable, Prefilled Syringes), Usability (Reusable, Disposable Syringes)], Self Injectors [Needle-Free, Autoinjectors, Pen, Wearable Injectors], Topical [Liquid (Solutions, Suspensions), Semi-Solid (Creams, Gels, Ointments, Pastes, Lotions), Solid (Suppositories, Powders), Transdermal (Patches, Gels)], Ocular (Liquid, Semi-Solid), Ocular (Drug-Coated Contact Lenses, Ocular Inserts], Pulmonary [Metered-Dose Inhalers, Dry Powder Inhaler, Nebulizers (Jet, Ultrasonic, Soft Mist Nebulizers)], Nasal [Drops, Sprays, Powders, Gels], Transmucosal [Oral (Buccal, Sublingual), Rectal, Vaginal], Implantable [Active, Passive]}, By Application (Infectious Diseases, Cancer, Cardiovascular, Diabetes, Respiratory, Central Nervous System Disorders, Autoimmune Disease), Facility Of Use (Hospitals, Ambulatory Surgery Centers/Clinics, Home Care Settings, Diagnostic Centers), By region, Competitive Landscape - Global Forecast to 2032” in detail along with the table of contents:

Increasing burden of cardiovascular disease on healthcare systems

The pharmaceutical drug delivery industry share from the cardiovascular diseases segment is predicted to record over 7.2% CAGR by 2032. Cardiovascular diseases have become more common and are estimated to be responsible for 17.9 million fatalities annually. Drug delivery plays a vital role in the overall treatment of cardiovascular diseases. Oral drug delivery, injectable drug delivery, and implanted drug delivery are some of the popular options that can be used for successful therapy.

A surge in patient footfall across diagnostic centers

The pharmaceutical drug delivery market share from the diagnostic centers segment is expected to reach more than USD 194.5 billion by 2032. The market for diagnostic centers has grown due to the increasing frequency of infectious and chronic disorders. Infectious diseases like the COVID-19 virus, among others, are influencing the rate of disease spread. Diagnostic centers help patients suffering from such diseases recover with an appropriate treatment plan.

Development of new products in the Europe region

Europe pharmaceutical drug delivery industry size is predicted to surpass USD 792.5 billion by 2032. The growing elderly population and rising healthcare spending will aid in market expansion. Additionally, the market will develop technologically advanced products for the healthcare sector. Large pharmaceutical manufacturers are also located across Europe, which will support the regional industry expansion.

Competitive landscape of the global pharmaceutical drug delivery market

Pfizer Inc., GILEAD SCIENCES, INC., Johnson & Johnson, AbbVie Inc, Eli Lilly and Company, Merck & Co. Inc., Sanofi, Amgen, Inc., AstraZeneca plc, and Bayer AG, are some of the key players in the market.

Authors: Mariam Faizullabhoy, Gauri Wani